SER logo

Serina Therapeutics, Inc.

SER
Healthcare|Biotechnology|US
$1.38
-0.27 (-16.36%)
DCF Value
$0.10
Tangible Book / Share
$1.14
Cash / Share
$1.41
Next Earnings Report
Nov 18, 2026
EPS est. -$0.34
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Aug 24, 2026 (S-1). Possible dilution.

Upcoming Data Readouts (1)

Jan 2027
Est. completion
P1PARKINSON DISEASE (Disorder)
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
NCT07422675n=40

Recent Press Releases

Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
Nov 4, 2026 · GlobeNewsWire
Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
Nov 3, 2026 · GlobeNewsWire
Custom Truck One Source, Inc. Reports Record Third Quarter 2026 Results and Increases Full Year 2026 Adjusted EBITDA and SER Revenue Guidance
Oct 26, 2026 · Business Wire
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Oct 15, 2026 · GlobeNewsWire
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"
Sep 23, 2026 · GlobeNewsWire
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 10, 2026 · GlobeNewsWire
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2
Sep 9, 2026 · GlobeNewsWire
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 13, 2026 · GlobeNewsWire

SEC Filings (80)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 3, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Oct 9, 20268-KMaterial eventDocumentIndex
Sep 9, 20268-KMaterial eventDocumentIndex
Aug 31, 2026EFFECTDocumentIndex
Aug 27, 20268-KMaterial eventDocumentIndex
Aug 24, 2026S-1IPO / offering registrationDocumentIndex
Aug 13, 2026S-8Employee stock planDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Jul 23, 20268-KMaterial eventDocumentIndex
Jul 22, 20268-KMaterial eventDocumentIndex
Jul 22, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jun 24, 20268-KMaterial eventDocumentIndex
Jun 3, 2026EFFECTDocumentIndex
May 22, 2026S-3Shelf registrationDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 4, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 27, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 21, 20268-KMaterial eventDocumentIndex
Apr 17, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 27, 202610-K/AAnnual reportDocumentIndex
Mar 25, 2026S-8Employee stock planDocumentIndex
Mar 25, 20268-KMaterial eventDocumentIndex
Mar 25, 202610-KAnnual reportDocumentIndex
Mar 23, 20268-KMaterial eventDocumentIndex
Feb 13, 2026EFFECTDocumentIndex
Jan 30, 2026S-3Shelf registrationDocumentIndex
Jan 28, 20268-KMaterial eventDocumentIndex
Jan 15, 20268-KMaterial eventDocumentIndex
Dec 10, 20258-KMaterial eventDocumentIndex
Nov 13, 20258-KMaterial eventDocumentIndex
Nov 13, 202510-QQuarterly reportDocumentIndex
Nov 12, 20258-KMaterial eventDocumentIndex
Nov 3, 20258-KMaterial eventDocumentIndex
Oct 27, 2025DEFR14ADocumentIndex
Oct 6, 20258-KMaterial eventDocumentIndex
Sep 26, 2025DEFA14AProxy / shareholder voteDocumentIndex
Sep 26, 2025DEF 14AProxy / shareholder voteDocumentIndex